ABSK-043 is under clinical development by Abbisko Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

TNB-738 is under clinical development by Ancora Biotech and currently in Phase I for Unspecified Immunological Disorders.

Insulin lispro U100 is under clinical development by Adocia and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes).

Plasmodium Immunotherapy is under clinical development by CAS-Lamvac Biotech and currently in Phase II for Liver Cancer.

RP-7214 is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer.